The Symptoms Of Multiple Sclerosis Blog

Information and Resources on Multiple Sclerosis and its signs and symptoms!
English flagItalian flagKorean flagChinese (Simplified) flagPortuguese flagGerman flagFrench flagSpanish flagJapanese flagArabic flagRussian flagGreek flagDutch flagBulgarian flagCzech flagCroat flagDanish flagFinnish flagHindi flagPolish flagRumanian flagSwedish flagNorwegian flag
By N2H

Opexa Therapeutics Reports Favorable Two-Year Data In Phase I/II Retreatment Studies Of Tovaxin(R) For Multiple Sclerosis June 16, 2008

Filed under: MS — The Symptoms Of Multiple Sclerosis Blog @ 6:57 am

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a cell therapy development and commercialization company, announced favorable safety and efficacy data for Tovaxin®, the Company’s investigational T-cell vaccination therapy for multiple sclerosis (MS), in the second year of open-label clinical retreatment studies in patients with MS.

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • StumbleUpon
  • Technorati


add to del.icio.usPrint This Post Print This Post

Leave a Reply